Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Normal Volunteers
| Status: | Recruiting |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 2/23/2019 |
| Start Date: | April 28, 2010 |
| Contact: | Patricia L Littel, R.N. |
| Email: | plittel@cc.nih.gov |
| Phone: | (301) 402-5964 |
Collection of Peripheral Blood Stem Cells Using G-CSF and Plerixafor in Healthy Volunteers
Background:
- Many treatments for immune system disorders involve the use of stem cells that have been
collected from blood marrow. To obtain these stem cells without surgery, individuals
receive granulocyte colony-stimulating factor (G-CSF) to encourage the production of
stem cells that can be collected through blood donations. However, not all patients or
normal donors respond to G-CSF alone.
- Plerixafor, recently approved by the Food and Drug Administration, is different from
G-CSF but also allows stem cells to be collected from donated blood. However, more
research is needed on the quality and viability of the stem cells collected after using
both G-CSF and plerixafor.
Objectives:
- To collect and study the blood cells produced after treatment with G-CSF and plerixafor in
healthy volunteers.
Eligibility:
- Healthy volunteers between 18 and 65 years of age who are eligible to donate blood.
Design:
- Participants will be screened with a medical history, physical examination, and initial
blood tests.
- At the start of the study cycle, participants will receive daily morning injections of
G-CSF for 5 days. These may be given at the clinical center or by the participant after
teaching, depending on the participant s preference.
- On the morning of Day 4, participants will visit the clinical center to provide a blood
sample after the injection. On the evening of Day 4, participants will receive an
injection of plerixafor.
- Participants will have the final injection of G-CSF on the morning of Day 5, and will
provide another blood sample.
- On Day 5, participants will have apheresis to separate the stem cells from the rest of
the blood. The apheresis may take up to 5 hours to complete.
- The study will end after a follow-up phone call 7 to 14 days after the apheresis
procedure.
- Many treatments for immune system disorders involve the use of stem cells that have been
collected from blood marrow. To obtain these stem cells without surgery, individuals
receive granulocyte colony-stimulating factor (G-CSF) to encourage the production of
stem cells that can be collected through blood donations. However, not all patients or
normal donors respond to G-CSF alone.
- Plerixafor, recently approved by the Food and Drug Administration, is different from
G-CSF but also allows stem cells to be collected from donated blood. However, more
research is needed on the quality and viability of the stem cells collected after using
both G-CSF and plerixafor.
Objectives:
- To collect and study the blood cells produced after treatment with G-CSF and plerixafor in
healthy volunteers.
Eligibility:
- Healthy volunteers between 18 and 65 years of age who are eligible to donate blood.
Design:
- Participants will be screened with a medical history, physical examination, and initial
blood tests.
- At the start of the study cycle, participants will receive daily morning injections of
G-CSF for 5 days. These may be given at the clinical center or by the participant after
teaching, depending on the participant s preference.
- On the morning of Day 4, participants will visit the clinical center to provide a blood
sample after the injection. On the evening of Day 4, participants will receive an
injection of plerixafor.
- Participants will have the final injection of G-CSF on the morning of Day 5, and will
provide another blood sample.
- On Day 5, participants will have apheresis to separate the stem cells from the rest of
the blood. The apheresis may take up to 5 hours to complete.
- The study will end after a follow-up phone call 7 to 14 days after the apheresis
procedure.
Hematopoietic stem cells that have been mobilized from the bone marrow into the peripheral
circulation are readily collected by apheresis, and may be used for several purposes. They
are used for allogeneic and autologous transplantation and are often manipulated in various
ways depending on the goal of the transplant. Gene therapy for immunodeficiencies relies on
the collection of these cells.
Traditionally, mobilization has been done using granulocyte colony stimulating factor
(G-CSF). However not all patients or normal donors respond to GCSF alone. Plerixafor, a
recently Food and Drug Administration (FDA) approved drug, has a unique mode of action
distinct from that of GCSF, but also results in mobilization of peripheral blood progenitors
into the circulation, allowing their collection by standard apheresis. The quality of these
cells for transduction using viral vectors in anticipation of gene therapy uses has not been
thoroughly assessed, and there are theoretical considerations why vectors that use various
envelopes for cell binding may be affected by the use of this CXCR4 antagonist. In order to
be able to assess the transduction and engraftment of these cells in murine models, we will
perform collection and mobilization on 5 healthy volunteers at the NIH Clinical Center using
the FDA approved medications G-CSF and plerixafor.
circulation are readily collected by apheresis, and may be used for several purposes. They
are used for allogeneic and autologous transplantation and are often manipulated in various
ways depending on the goal of the transplant. Gene therapy for immunodeficiencies relies on
the collection of these cells.
Traditionally, mobilization has been done using granulocyte colony stimulating factor
(G-CSF). However not all patients or normal donors respond to GCSF alone. Plerixafor, a
recently Food and Drug Administration (FDA) approved drug, has a unique mode of action
distinct from that of GCSF, but also results in mobilization of peripheral blood progenitors
into the circulation, allowing their collection by standard apheresis. The quality of these
cells for transduction using viral vectors in anticipation of gene therapy uses has not been
thoroughly assessed, and there are theoretical considerations why vectors that use various
envelopes for cell binding may be affected by the use of this CXCR4 antagonist. In order to
be able to assess the transduction and engraftment of these cells in murine models, we will
perform collection and mobilization on 5 healthy volunteers at the NIH Clinical Center using
the FDA approved medications G-CSF and plerixafor.
- INCLUSION CRITERIA:
To be eligible to participate in this study, a subject must satisfy all of the following
criteria:
1. The subject must be a healthy adult aged 18-65 years, and weighing at least 50 kg.
2, The subject must have normal renal function (creatinine <1.5 mg/dL; <1 plus
proteinuria); normal hepatic function (bilirubin < 1.5 mg/dL); normal hematologic function
(WBC greater than or equal to 2500/mm(3); granulocytes greater than or equal to 1200/mm(3);
platelets greater than or equal to 120,000; hematocrit greater than or equal to 38).
3. A female of childbearing potential may be entered if she is using 1 or 2 forms of
effective contraception (depending on the type of contraception), and has a negative serum
pregnancy test within 1 week of beginning G-CSF administration.
4. The subject must be willing to allow blood cell samples to be stored.
EXCLUSION CRITERIA:
A subject will be ineligible to participate in this study if any of the following criteria
are met:
1. The subject has a temperature > 38 degrees Celsius, or WBC > 9000/mm(3).
2. A female who is pregnant or lactating as determined by history and/or pregnancy test.
3. The subject has a history of vasculitis, uncontrolled hypertension, or symptomatic
coronary artery disease, or similar disorders.
4. The subject has a positive test result for any of the following: human
immunodeficiency virus (HIV) I & II antibody, hepatitis C virus (HCV) antibody,
hepatitis B soluble antigen (HBSAg), or the rapid plasma reagin (RPR) test for
syphilis.
5. The subject lacks peripheral venous access in arm veins adequate for apheresis.
6. The subject is currently participating in other research studies.
7. The subject may be excluded at the discretion of the Principal Investigator (PI).
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 301-402-1773
Click here to add this to my saved trials
